Supplementary Table 1. Detailed pathologic diagnosis of included studies

Study	No of	Liposarcoma			1110) (D) (CT	0.1	No of	Liposarcoma				1116) (D) (GT	04	
	SA	WDLPS	DDLPS	OLPS	Total	- LMS	MPNST	Other	preRT+S	WDLPS	DDLPS	OLPS	Total	- LMS	MPNST	Other
De Wever et al., 2013 ²⁷	30	14	16	0	30	0	0	0	29	16	13	0	29	0	0	0
Stucky et al., 2014 ³¹	26	19*	24*	ND	43*	8*	0	12*	37	19*	24*	ND	43*	8*	0	12*
Kelly et al. 2015 ²¹	172	54	63	0	117	49	3	3	32	6	13	0	19	8	1	4
Lane et al., 2015 ¹⁴	45	13	5	2	20	10	0	15	29	2	4	5	11	12	0	6
Ecker et al., 2016 ²⁸	173	ND	ND	ND	173	0	0	0	174	ND	ND	ND	174	0	0	0
Molina et al., 2016 ¹⁹	14	5	7	2	14	0	0	0	27	8	19	0	27	0	0	0
Nussbaum et al., 2016 ^{30‡}	1,126	168	293	0	461	311	8	346	563	83	128	0	211	153	10	189
Chouliaras et al., 2019 ²⁶	294	50	54	12	116	82	3	83	56	3	16	0	19	17	0	20
Bachmann et al., 2020 ²⁴	4	0	4	0	4	0	0	0	6	0	6	0	6	0	0	0
Bonvalot et al., 2020 ¹⁷	133	42	54	4	100	22	ND	11	133	46	51	1	98	16	ND	18
Bredbeck et al., 2022 ²⁵	72	27	17	4	48	17	0	7	17	1	6	1	8	6	0	3
Callegaro et al., 2022 ^{18§}	101	9	51	0	60	14	0	27	101	9	54	0	63	13	0	25
Erstad et al., 2023 ²⁹	249	104	1450	0	249	0	0	0	249	104	145	0	249	0	0	0
Total	2,439	486	709	24	1,392	505	14	492	1,453	278	455	7	914	225	11	265

Abbreviations: No, number; SA, surgery alone; PreRT+S, preoperative radiotherapy combined with surgery; WDLPS, well-differentiated liposarcoma; DDLPS, dedifferentiated liposarcoma; LMS, leiomyosarcomas; MPNST, malignant peripheral nerve sheath tumors; ND, not described.

^{*}Total number of both groups.

						1			. 0	one
						+			· r	Favors Surgery Alone
Odds ratio and 95% CI	rvival	Τ	+	2 Favors S						
tio anc	of 5-year Survival	+	+	+	<u> </u>	ŧ	+		· -	
Odds ra	of 5-y	╀	+	+	Ţ	1			0.5	eRT+S
		<u> </u>		1		+			0.2	Favors PreRT+S
						<u> </u>			0.1	
	Relative weight	7.77	8.66	8.14	46.98	1.60	26.85			
Alive / Total Statistics for each study	I -Value	0.468	1.000	0.123	0.175	0.930	0.595	0.199		
	Jpper Iimit Z-Value p-Value weight	-0.725	0.000	-1.543	-1.356	0.088	0.532	-1.285		
	Upper Iimit	1.976	2.784	0.151 1.252	0.475 1.145	12.097	0.655 2.094	1.109	00.	
	Odds Lower Upper ratio limit	0.227	0.359	0.151	0.475	0.103 12.097		0.821 0.607 1.109	$1\%, T^2 = 0$	
	Odds ratio	0.670	1.000	0.435	0.738	1.114	1.171	0.821	11), $I^2 = 0$	
	Odds PreRT+S ratio	20 / 29	22 / 37	22 / 29	104 / 173 117 / 174 0.738	13 / 14 25 / 27 1.114	102 / 133		$= 5(P = 0.6^2)$	
	Surgery Alone	3 18 / 30	16 / 26	27 / 45	104 / 173	13 / 14	106 / 133		= 3.384, df) ! !
Study name		De Wever et al., 2013 18 / 30 20 / 29 0.670 0.227 1.976	Stucky et al., 2014	Lane et al., 2015	Ecker et al., 2016	Molina et al., 2016	Bonvalot et al., 2020 106 / 133 102 / 133 1.171	Pooled	Heterogeneity: $Chi^2 = 3.384$, $df = 5(P=0.641)$, $I^2 = 0\%$, $T^2 = 0.00$ Test for overall effect: $Z = 1.285$ ($P = 0.199$)	

Supplementary Figure 1. Forest plots of overall survival. In the preoperative radiotherapy combined with surgery (preRT+S) group, overall survival tended to be longer in patients with retroperitoneal sarcoma, liposarcoma, and the subgroup of patients with well-differentiated liposarcoma and grade 1–2 dedifferentiated liposarcoma (WDLPS and G1-2DDLPS). However, in all comparisons, the difference in overall survival was not significant.